Utility and Validity of a High-intensity, Intermittent Exercise Protocol

November 19, 2021 updated by: University Ghent

The Utility and Validity of a High-intensity, Intermittent Exercise Protocol in Male Jumping Athletes

The purpose of this study is to identify an exercise-induced fatigue protocol to mimic central and peripheral acute fatigue effects associated with participation in vigorous dynamic sports activities and to understand the expected central (cardiovascular) and peripheral (muscular) impact of this protocol.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Fatigue-related parameters (BORG, heart rate, blood lactate level, concentric/eccentric force of the quadriceps muscle) will be measured before and after different short-term high-intensity, intermittent exercise protocols.

Study Type

Interventional

Enrollment (Actual)

20

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Oost-Vlaanderen
      • Gent, Oost-Vlaanderen, Belgium, 9000
        • Vakgroep Revalidatiewetenschappen

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 45 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Male

Description

Inclusion Criteria:

  • Men
  • ≥ 18 years
  • Volley- and basketball, non-elite
  • ≥ 3 times per week sports participation
  • No acute or overuse low back/lower extremity injuries in the past 6 months

Exclusion Criteria:

  • Women
  • <18 years
  • >45 years
  • other sports than volley- and basketball
  • elite players
  • <3 times per week sports participation
  • acute or overuse low back/lower extremity injuries in the past 6 months

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Screening
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: All-out, high-intensity, intermittent exercise protocol
During the fatigue protocol, participants will sprint forward 5 m, cut at a 90° angle, sprint forward another 5 m, and backpedal 5 m. This activity will be repeated 4 times before participants will complete a series of hurdle activities. First, they will perform 2-legged jumps over 5 hurdles that are 30 cm high, turn, and repeat the jumps. Second, they will perform side-stepping exercises over the 5 hurdles. Third, they will complete four 5-m lateral shuffles.
Experimental: 5 min, high-intensity, intermittent exercise protocol
During the fatigue protocol, participants will sprint forward 5 m, cut at a 90° angle, sprint forward another 5 m, and backpedal 5 m. This activity will be repeated 4 times before participants will complete a series of hurdle activities. First, they will perform 2-legged jumps over 5 hurdles that are 30 cm high, turn, and repeat the jumps. Second, they will perform side-stepping exercises over the 5 hurdles. Third, they will complete four 5-m lateral shuffles.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Heart rate
Time Frame: This parameters will be continuously monitored 10 minutes before the start of the fatigue protocol until 30 minutes after completion of the protocol
Heart rate, expressed in beats per minute
This parameters will be continuously monitored 10 minutes before the start of the fatigue protocol until 30 minutes after completion of the protocol
Isokinetic dynamometry
Time Frame: This parameter will be monitored 10 minutes before the start of the fatigue protocol
Isokinetic dynamometry of the quadriceps muscle
This parameter will be monitored 10 minutes before the start of the fatigue protocol
Isokinetic dynamometry
Time Frame: This parameter will be monitored immediately after completion of the protocol
Isokinetic dynamometry of the quadriceps muscle
This parameter will be monitored immediately after completion of the protocol
Isokinetic dynamometry
Time Frame: This parameter will be monitored 15 minutes after completion of the protocol
Isokinetic dynamometry of the quadriceps muscle
This parameter will be monitored 15 minutes after completion of the protocol
Isokinetic dynamometry
Time Frame: This parameter will be monitored 30 minutes after completion of the protocol
Isokinetic dynamometry of the quadriceps muscle
This parameter will be monitored 30 minutes after completion of the protocol
Blood lactate level
Time Frame: This parameters will be monitored 10 minutes before the start of the fatigue protocol
Blood lactate level, expressed in millimol per liter
This parameters will be monitored 10 minutes before the start of the fatigue protocol
Blood lactate level
Time Frame: This parameters will be monitored 10 minutes after completion of the protocol
Blood lactate level, expressed in millimol per liter
This parameters will be monitored 10 minutes after completion of the protocol
BORG
Time Frame: This parameters will be continuously monitored 10 minutes before the start of the fatigue protocol until 30 minutes after completion of the protocol
BORG-score, indicating the rate of perceived exertion for legs and breathlessness
This parameters will be continuously monitored 10 minutes before the start of the fatigue protocol until 30 minutes after completion of the protocol

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Circuit time
Time Frame: Time will be recorded immediately after completion of the fatigue protocol
Time to perform the fatigue protocol
Time will be recorded immediately after completion of the fatigue protocol

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 7, 2020

Primary Completion (Actual)

June 30, 2021

Study Completion (Actual)

November 19, 2021

Study Registration Dates

First Submitted

August 13, 2020

First Submitted That Met QC Criteria

August 25, 2020

First Posted (Actual)

August 31, 2020

Study Record Updates

Last Update Posted (Actual)

November 22, 2021

Last Update Submitted That Met QC Criteria

November 19, 2021

Last Verified

November 1, 2021

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • BC-07679

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

Undecided

IPD Plan Description

This is not yet decided.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Fatigue

Clinical Trials on Fatigue protocol

Subscribe